49
Participants
Start Date
May 26, 2014
Primary Completion Date
June 1, 2015
Study Completion Date
June 1, 2015
Insulin icodec
Administered once-weekly subcutaneously (s.c., under the skin) for 35 days
insulin degludec
Administered once-daily subcutaneously (s.c., under the skin) for 35 days
placebo
Administered subcutaneously (s.c., under the skin) once-daily for 35 days
Novo Nordisk Investigational Site, Neuss
Lead Sponsor
Novo Nordisk A/S
INDUSTRY